Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings can read like a graduate textbook—especially when Acrivon Therapeutics packs its 10-K with proteomics jargon, trial protocols, and liquidity tables. If you’re searching “Acrivon Therapeutics SEC filings explained simply” or wondering how platinum-resistant ovarian cancer data affects the balance sheet, you’re in the right place. Stock Titan’s AI dissects every page the moment it hits EDGAR, so you spend minutes—not hours—finding what matters.
Need to track “Acrivon Therapeutics insider trading Form 4 transactions” before the next readout? Our dashboard streams Form 4 insider transactions in real time, flags option exercises, and links them to upcoming milestones disclosed in 8-Ks. Curious about cash runway? The quarterly earnings report 10-Q filing is paired with plain-English summaries that spotlight R&D spend, burn rate, and AP3 platform progress. We also map risk-factor changes between annual report 10-K filings, highlight any shelf-registration clues in S-3s, and surface board votes from the latest proxy statement on executive compensation.
Whether you’re parsing an “Acrivon Therapeutics earnings report filing analysis,” monitoring “Acrivon Therapeutics executive stock transactions Form 4,” or decoding an “Acrivon Therapeutics 8-K material events explained,” Stock Titan delivers comprehensive coverage. Our AI-powered summaries translate dense pathway diagrams into actionable insights, while expert commentary points out dilution risk and regulatory catalysts. Set custom alerts to know the second a new study start appears, compare segment performance across periods, and keep a pulse on WEE1/PKMYT1 clinical updates. All ACRV filings, all in one place, always up to date.
Nelnet, Inc. (NNI) – Form 4 filed 07/21/2025
Director and >10% owner Angela L. Muhleisen reported a Code G gift of 41,250 Class A shares on 07/17/2025 at $0.00 per share. Her direct holdings fall to 972,199 shares (down c. 4%).
She continues to report ~2.23 million additional shares held indirectly through her late spouse’s estate (1.23 m) and multiple dynasty trusts/GRATs, bringing total reported beneficial ownership to roughly 3.2 million shares. The filing states that 857,353 shares held by her adult son and 869,025 shares held by her adult daughter are no longer included in her reportable holdings.
No open-market sales, purchases, or derivative transactions were disclosed; the activity appears related to estate or family wealth planning and is unlikely to affect Nelnet’s capital structure or liquidity.
FAQ
What is the current stock price of Acrivon Therapeutics (ACRV)?
What is the market cap of Acrivon Therapeutics (ACRV)?
What is the primary focus of Acrivon Therapeutics?
How does the AP3 platform work?
What are Acrivon’s key pipeline programs?
How does Acrivon select patients for its clinical trials?
What differentiates ACR-368 from other oncology therapies?
How does Acrivon support its drug development process?
What role do companion diagnostics play in Acrivon’s strategy?
How is Acrivon positioned within the competitive precision oncology landscape?
